MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A.
Horiuchi D, et al. Among authors: chandriani s.
J Exp Med. 2012 Apr 9;209(4):679-96. doi: 10.1084/jem.20111512. Epub 2012 Mar 19.
J Exp Med. 2012.
PMID: 22430491
Free PMC article.